# FGB Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *FGB* gene encodes the β-chain of fibrinogen, a critical protein for hemostasis, wound healing, and inflammation, with its expression primarily regulated by IL-6 and glucocorticoids in hepatocytes. - Pathogenic variants in *FGB* lead to congenital fibrinogen disorders (CFDs) such as afibrinogenemia and hypofibrinogenemia, characterized by bleeding diatheses, and can also contribute to thrombotic risk through dysfibrinogenemia. - Fibrinogen, via its Bβ chain, interacts with cellular receptors like integrin αIIbβ3 and TLR4, mediating platelet aggregation, leukocyte adhesion, and innate immune responses, linking coagulation to inflammation. - Polymorphisms in the *FGB* promoter, particularly rs1800790 (−455G>A), are associated with altered fibrinogen levels and modulate the risk of cardiovascular diseases, stroke, and COVID-19 severity due to their impact on inflammatory cytokine production and thrombotic potential. - Diagnostic evaluation for *FGB*-related disorders involves functional and antigenic fibrinogen assays, alongside genetic sequencing of *FGA*, *FGB*, and *FGG* to differentiate quantitative and qualitative defects. - Therapeutic strategies for *FGB*-related bleeding disorders include fibrinogen concentrate replacement, while investigational approaches like antisense oligonucleotides and gene therapy aim to correct underlying genetic defects. --- ## Executive Summary & Key Metadata The **FGB gene** encodes the β-chain (Bβ) of fibrinogen, a 340-kDa hexameric glycoprotein essential for hemostasis, wound healing, and inflammatory responses. Fibrinogen is composed of two sets of three polypeptide chains—Aα, Bβ, and γ—encoded by the paralogous genes *FGA*, *FGB*, and *FGG*, respectively. The Bβ chain, encoded by *FGB*, is the rate-limiting component in the hepatic assembly and secretion of the mature hexamer. Pathogenic variants in *FGB* produce a spectrum of congenital fibrinogen disorders (CFDs), ranging from asymptomatic hypofibrinogenemia to severe afibrinogenemia with life-threatening hemorrhage. Beyond hemostasis, *FGB* polymorphisms modulate cardiovascular, obstetric, oncologic, and infectious disease risk, positioning this gene as a critical node in the genotype–phenotype architecture of complex disease. | **Attribute** | **Value** | |---|---| | HGNC Symbol | FGB | | UniProt Accession | P02675 | | Representative PDB ID | 3GHG (fibrinogen fragment) | | Chromosomal Locus | 4q31.3 | | Gene Size | ~8.2 kb (genomic) | | mRNA Length | 1,917 bp (NM_005141.5) | | Primary Molecular Function | Coagulation factor; structural component of fibrin clot; ligand for integrin αIIbβ3 and TLR4 | | Disease Associations | Congenital afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia; thrombosis; stroke; myocardial infarction; recurrent pregnancy loss | | Expression | Hepatocyte-specific (high); minor expression in megakaryocytes and epithelial cells | | Regulation | IL-6, glucocorticoids, hepatocyte nuclear factors; promoter SNPs rs1800790, rs1800787 | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *FGB* gene maps to the long arm of chromosome 4 at band q31.3, embedded within a tightly clustered fibrinogen gene locus spanning approximately 50 kb. The locus is arranged in the order: *FGG* (centromeric) – *FGA* – *FGB* (telomeric). This clustering is evolutionarily conserved across vertebrates and facilitates coordinated transcriptional regulation through shared cis-regulatory elements. The *FGB* gene itself spans 8,214 base pairs and contains 8 exons separated by 7 introns. Exon sizes range from 57 bp (exon 2) to 1,100 bp (exon 8, which contains the 3′ untranslated region). The translation initiation codon resides in exon 1, and the termination codon is positioned in exon 8. The promoter region of *FGB* lacks a canonical TATA box but contains a CCAAT box and multiple binding sites for liver-enriched transcription factors, including hepatocyte nuclear factor 1 (HNF-1), HNF-3, HNF-4, and C/EBP. The proximal promoter (−300 to +1 relative to the transcription start site) harbors two critical polymorphic sites: **rs1800790** (−455G>A) and **rs1800787** (−148C>T). These single-nucleotide polymorphisms (SNPs) are in strong linkage disequilibrium and exert additive effects on basal and IL-6-stimulated *FGB* transcription. The −455A allele disrupts a consensus HNF-1 binding site, paradoxically increasing promoter activity in reporter assays, likely through altered chromatin conformation and recruitment of alternative transcription factors [1, 2, 3]. ### 1.2 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation sequencing (ChIP-seq) data from primary human hepatocytes reveal that the *FGB* promoter is marked by H3K4me3 and H3K27ac, consistent with active transcription. An enhancer element located ~1.5 kb upstream of the transcription start site binds STAT3 in response to IL-6 signaling, providing a mechanistic link between inflammation and fibrinogen upregulation [4]. Additionally, a liver-specific super-enhancer spanning the intergenic region between *FGA* and *FGB* coordinates the expression of all three fibrinogen genes. Quantitative trait locus (QTL) analyses demonstrate that the rs1800790 genotype influences both splicing efficiency and histone modification density at this locus, with the A allele associated with increased H3K27ac occupancy in hepatocyte models [2]. ### 1.3 Alternative Splicing and Isoforms The primary *FGB* transcript undergoes constitutive splicing to produce a single major mRNA species of 1,917 nucleotides. However, RNA-seq data from human liver tissue have identified low-abundance alternatively spliced isoforms, including a transcript retaining intron 6 (predicted to encode a truncated Bβ chain lacking the C-terminal globular domain) and a transcript with alternative 5′ splice site usage in exon 2. These minor isoforms are subject to nonsense-mediated decay and are unlikely to contribute significantly to the fibrinogen pool. In contrast, the *FGG* gene produces two major splice variants (γA and γ′), which differentially incorporate into the hexamer and modulate fibrin clot structure. The Bβ chain, by contrast, is invariant in the mature protein, underscoring its structural rigidity and functional indispensability [4]. ### 1.4 Pseudogenes and Homologs No processed pseudogenes of *FGB* have been annotated in the human genome. Orthologs are present in all jawed vertebrates, with high sequence conservation in the C-terminal fibrinogen-related domain (FReD). The *FGB* gene in birds (e.g., *Macrocephalon maleo*) has been used as a molecular marker for phylogenetic inference due to its moderate evolutionary rate and conserved intron–exon structure [5]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Post-Translational Processing The *FGB* gene product is synthesized as a pre-pro-protein of 491 amino acids, including a 20-residue signal peptide and a 27-residue N-terminal pro-peptide. Following cleavage by signal peptidase in the endoplasmic reticulum (ER), the pro-peptide is removed by furin-like proteases during secretion. The mature Bβ chain comprises 444 amino acids with a molecular mass of ~56 kDa (reduced). The protein is N-glycosylated at Asn-394, a modification essential for proper folding and intracellular transport. The Bβ chain contains 11 cysteine residues, all of which participate in disulfide bonding: six form intra-chain bonds, while five contribute to inter-chain linkages that stabilize the hexameric structure. ### 2.2 Domain Architecture The Bβ chain is organized into four distinct structural domains, from N-terminus to C-terminus: 1. **N-terminal globular domain (residues 1–62)**: This region contains the "coiled-coil connector" and participates in the central E region of the fibrinogen molecule. It includes the thrombin cleavage site at Arg-14–Gly-15, which releases fibrinopeptide B (FPB) during coagulation. The N-terminus also harbors the calcium-binding site that stabilizes the E region. 2. **Coiled-coil domain (residues 63–192)**: A 130-residue α-helical segment that intertwines with the corresponding Aα and γ chains to form a triple-helical coiled-coil. This domain is critical for hexamer assembly and provides mechanical flexibility to the molecule. The coiled-coil contains two inter-chain disulfide rings (at residues 65–69 and 189–193) that covalently link the three chains. 3. **Plasmin-sensitive linker (residues 193–250)**: A flexible, protease-sensitive region connecting the coiled-coil to the C-terminal domain. This region is susceptible to cleavage by plasmin, elastase, and matrix metalloproteinases, generating degradation products that modulate inflammation and angiogenesis. 4. **C-terminal fibrinogen-related domain (FReD; residues 251–444)**: A globular β-sandwich structure homologous to the C-terminal domains of other fibrinogen family members (e.g., tenascins, ficolins). The FReD contains the "hole b" polymerization pocket, which interacts with the "knob B" sequence (GHRP) exposed after FPB cleavage. This knob-hole interaction drives lateral aggregation of fibrin protofibrils and is essential for clot formation. The FReD also contains a high-affinity calcium-binding site and a lectin-like groove that mediates interactions with pathogens and cellular receptors. ### 2.3 Quaternary Structure and Fibrinogen Assembly The mature fibrinogen hexamer (AαBβγ)₂ is assembled in the ER through a stepwise process: (1) Aα and γ chains form an Aα-γ dimer; (2) the Bβ chain is incorporated to form a half-molecule (AαBβγ); (3) two half-molecules dimerize through antiparallel alignment of the N-terminal regions, forming the central E domain and two peripheral D domains. The Bβ chain is the rate-limiting component in this assembly; in its absence, Aα-γ dimers accumulate in the ER and are degraded via the proteasome. This explains why *FGB* null mutations cause afibrinogenemia with undetectable plasma fibrinogen, whereas *FGA* or *FGG* mutations may allow residual protein secretion [6, 7, 8]. The crystal structure of human fibrinogen (PDB: 3GHG) reveals that the Bβ FReD adopts a β-sandwich fold with two antiparallel β-sheets, one containing four strands and the other five. The "hole b" pocket is lined by residues Tyr-278, His-340, and Asp-381, which form hydrogen bonds with the GHRP knob. Mutations affecting these residues (e.g., p.Gly302Arg, p.Pro265Leu) disrupt polymerization and produce dysfibrinogenemia with thrombotic or hemorrhagic phenotypes [1, 9, 10]. ### 2.4 Interactive 3D Visualization [Interactive 3D Protein Visualizer: Load FGB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P02675) The interactive viewer enables exploration of the Bβ chain within the context of the full fibrinogen hexamer. Users can toggle between cartoon, surface, and electrostatic representations; highlight the FReD domain, coiled-coil, and thrombin cleavage site; and overlay pathogenic missense variants (e.g., p.Gly302Arg, p.Leu121Arg, p.Trp474Ter) to assess their structural impact. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Biosynthesis and Secretion *FGB* expression is restricted primarily to hepatocytes, where it is constitutively transcribed at high levels. The rate of fibrinogen synthesis is regulated at both transcriptional and post-transcriptional levels. IL-6, the principal cytokine inducer, activates the JAK/STAT3 pathway, leading to STAT3 phosphorylation and binding to the *FGB* promoter. Glucocorticoids synergize with IL-6 by enhancing STAT3 transcriptional activity and stabilizing *FGB* mRNA. Conversely, IL-1β and TNF-α suppress *FGB* transcription by activating NF-κB, which competes with STAT3 for coactivator binding [4]. The half-life of *FGB* mRNA is ~8 hours, and its translation is coupled to the availability of free Aα and γ chains. Under acute-phase conditions, fibrinogen synthesis can increase 2- to 4-fold within 24 hours, driven by both transcriptional activation and enhanced mRNA stability. This rapid upregulation is clinically significant in sepsis, trauma, and malignancy, where hyperfibrinogenemia contributes to a prothrombotic state [2, 3, 4]. ### 3.2 Role in Coagulation Cascade Fibrinogen is the final substrate of the coagulation cascade. Thrombin cleaves FPA (from Aα) and FPB (from Bβ) to expose polymerization knobs. The removal of FPB is slower than FPA cleavage and is rate-limiting for lateral aggregation of protofibrils. The Bβ chain's "hole b" pocket interacts with the GHRP knob exposed after FPB release, driving the formation of thick, branched fibrin fibers. The resulting fibrin network is cross-linked by factor XIIIa, which introduces γ-glutamyl-ε-lysyl isopeptide bonds between adjacent chains, conferring mechanical strength and resistance to fibrinolysis. The Bβ chain also modulates fibrin clot structure independently of FPB cleavage. The Bβ Arg-14–Lys-15 sequence is a binding site for the antimicrobial peptide histidine-rich glycoprotein (HRG), and the Bβ coiled-coil interacts with fibronectin, influencing clot retraction and cell adhesion. ### 3.3 Cellular Signaling and Receptor Interactions Beyond its structural role, fibrinogen (and its degradation products) engages multiple cell-surface receptors to modulate cellular signaling: - **Integrin αIIbβ3 (GPIIb/IIIa)**: The C-terminal region of the Bβ chain contains an RGD-like sequence (Bβ 448–450: Arg-Gly-Asp) that supports platelet aggregation by cross-linking adjacent platelets. This interaction is the target of antiplatelet drugs such as abciximab and eptifibatide. - **Integrin αMβ2 (Mac-1)**: Fibrinogen binds to Mac-1 on monocytes and neutrophils via the Bβ chain, promoting leukocyte adhesion, transmigration, and phagocytosis. This interaction is critical for the inflammatory response and is implicated in atherosclerosis and ischemia-reperfusion injury. - **Toll-like receptor 4 (TLR4)**: Fibrinogen acts as an endogenous ligand for TLR4, activating NF-κB and MAPK pathways in macrophages. This triggers the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines, linking coagulation to innate immunity. The Bβ chain's FReD domain is the primary TLR4-binding site, and polymorphisms affecting this domain may alter inflammatory responses [3, 5, 6]. - **VE-cadherin**: Fibrinogen binds to VE-cadherin on endothelial cells, disrupting adherens junctions and increasing vascular permeability. This mechanism contributes to edema formation in inflammatory states. ### 3.4 Protein-Protein Interaction Network STRING analysis of the Bβ chain reveals a dense interaction network centered on the other fibrinogen chains (FGA, FGG) and coagulation factors (thrombin, factor XIIIa, plasminogen). Secondary interactors include: - **Fibronectin (FN1)**: Binds the coiled-coil region, mediating cell adhesion. - **Plasminogen (PLG)**: Binds the C-terminal domain, facilitating fibrinolysis. - **Integrin subunits (ITGA2B, ITGB3, ITGAM)**: Mediate platelet and leukocyte interactions. - **TGF-β1 (TGFB1)**: Co-regulated with fibrinogen in fibrotic diseases. - **SIRT1**: In renal cell carcinoma, SIRT1 downregulates FGB expression by destabilizing STAT3, revealing a tumor-suppressive axis [7]. BioGRID lists 23 physical interactions for the Bβ chain, including direct binding to thrombin (F2), factor XIIIa (F13A1), and the chaperone BiP (HSPA5) during ER folding. ### 3.5 Regulatory Feedback Loops Fibrinogen participates in a negative feedback loop with thrombin: thrombin cleaves fibrinogen to form fibrin, which then binds and sequesters thrombin within the clot matrix (antithrombin I activity). This reduces free thrombin concentration and limits further fibrin formation. Additionally, fibrin degradation products (FDPs) inhibit platelet aggregation and thrombin activity, providing a natural anticoagulant brake. The Bβ chain's susceptibility to plasmin cleavage ensures that this feedback operates efficiently, as FDPs are generated rapidly once fibrinolysis is initiated. ```mermaid sequenceDiagram participant LPS as "IL-6/Inflammation" participant R as "IL-6R/gp130" participant J as "JAK1/2" participant S as "STAT3" participant N as "Nucleus" participant FGB as "FGB Gene" participant ER as "ER/Golgi" participant FBG as "Fibrinogen Hexamer" participant T as "Thrombin" participant F as "Fibrin Clot" LPS->>R: IL-6 binding R->>J: gp130 dimerization J->>S: Phosphorylation (Y705) S->>N: Nuclear translocation N->>FGB: STAT3 binding to promoter FGB->>ER: mRNA translation ER->>FBG: Hexamer assembly & secretion FBG->>T: Substrate T->>F: FPB cleavage & polymerization F-->>T: Thrombin sequestration (antithrombin I) F-->>S: FDPs inhibit further synthesis ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Classification of Congenital Fibrinogen Disorders Congenital fibrinogen disorders are classified based on quantitative and qualitative defects: - **Afibrinogenemia** (OMIM #202400): Complete absence of fibrinogen; autosomal recessive; caused by homozygous or compound heterozygous null mutations. - **Hypofibrinogenemia** (OMIM #604835): Plasma fibrinogen <1.5 g/L; autosomal dominant or recessive; caused by heterozygous loss-of-function mutations. - **Dysfibrinogenemia** (OMIM #616004): Normal antigenic but reduced functional fibrinogen; autosomal dominant; caused by missense mutations affecting polymerization or thrombin cleavage. - **Hypodysfibrinogenemia**: Combined quantitative and qualitative defect. ### 4.2 Mutational Spectrum in FGB The *FGB* gene is the most frequently mutated fibrinogen gene in quantitative disorders, accounting for ~50% of afibrinogenemia cases and ~30% of hypofibrinogenemia cases. The mutational spectrum includes: **Nonsense mutations** (premature termination codons): - **c.1299G>A (p.Trp433Ter)**: Identified in a four-generation Chinese family with autosomal dominant hypofibrinogenemia. The mutation introduces a stop codon in the FReD domain, leading to a truncated Bβ chain that fails to assemble into the hexamer [8]. - **c.1421G>A (p.Trp474Ter)**: Reported in a Slovak patient with hypofibrinogenemia and bleeding phenotype. The truncated protein lacks the C-terminal 18 residues, disrupting the "hole b" pocket [8]. - **c.1105C>T (p.Gln339Ter)**: Found in a Venezuelan family with hypofibrinogenemia; the mutation eliminates the C-terminal half of the FReD domain [9]. - **c.1115T>A (p.Leu372Ter)**: Novel variant causing dysfibrinogenemia in two Chinese pedigrees [10]. **Missense mutations** (amino acid substitutions): - **p.Gly302Arg**: A founder mutation in Italian and Argentinean families causing afibrinogenemia. The substitution introduces a bulky charged residue into the β-sheet core of the FReD, destabilizing the domain and preventing secretion [1, 9]. - **p.Pro265Leu**: Reported in a Danish patient with hypofibrinogenemia and recurrent venous thrombosis. The mutation disrupts a conserved proline kink in the FReD, altering the conformation of the "hole b" pocket [10]. - **p.Leu121Arg**: Novel missense mutation in the coiled-coil domain causing hypofibrinogenemia. The substitution of a hydrophobic leucine with a charged arginine disrupts the hydrophobic core of the coiled-coil, impairing hexamer assembly [2]. - **p.Gly293Val**: Identified in a Chinese family with hypofibrinogenemia; the mutation affects a conserved glycine in the FReD, causing protein misfolding and ER retention [3]. - **p.Tyr416Cys and p.Ala68Thr**: Two novel variants characterized in Czech patients; the former introduces an unpaired cysteine in the FReD, while the latter disrupts the coiled-coil [1]. **Frameshift and splice-site mutations**: - **c.1299delG**: A frameshift mutation causing afibrinogenemia in a Turkish patient [6]. - **c.1421+1G>A**: A splice-donor mutation leading to exon skipping and a truncated protein [4]. - **Deep intronic mutation c.1244+332A>G**: Creates a consensus exonic splicing enhancer motif, resulting in aberrant mRNA splicing and afibrinogenemia. This mutation can be corrected in vitro with antisense oligonucleotides, highlighting a potential therapeutic approach [5]. **Deletions**: - **Whole-gene deletion**: A heterozygous deletion of the fibrinogen gene cluster (including *FGB*) was identified in a patient with hypofibrinogenemia and recurrent venous thrombosis [10]. - **Partial deletion**: A novel deletion in *FGB* causing hypofibrinogenemia was reported in a Thai family [4]. ### 4.3 Genotype–Phenotype Correlations The clinical phenotype of *FGB* mutations is highly variable, even within families carrying the same variant. Key observations: - **Null mutations** (nonsense, frameshift) typically cause afibrinogenemia when homozygous or compound heterozygous. Bleeding manifestations range from mild (easy bruising, menorrhagia) to severe (intracranial hemorrhage, umbilical cord bleeding). Paradoxically, some afibrinogenemic patients experience thrombotic events, possibly due to unopposed thrombin activity in the absence of fibrin's antithrombin I function [6, 7]. - **Missense mutations** in the FReD often cause dysfibrinogenemia with a thrombotic phenotype. For example, p.Pro265Leu was associated with recurrent venous thrombosis despite low fibrinogen levels, suggesting that the mutant protein exerts a dominant-negative effect on clot structure [10]. - **Promoter polymorphisms** (rs1800790, rs1800787) do not cause CFD but modulate fibrinogen levels by 7–15% per allele. The −455A allele is associated with higher fibrinogen levels and increased risk of ischemic stroke, coronary artery disease, and venous thromboembolism [6, 7, 8, 9, 10]. - **Co-inheritance of variants**: The phenotypic severity of *FGB* mutations can be modified by co-inherited variants in other coagulation genes (e.g., *F2*, *F5*, *PAI-1*). A patient with a heterozygous *FGB* deletion and hemizygous p.Pro265Leu variant mimicking homozygosity presented with recurrent thrombosis, illustrating the complexity of genotype–phenotype relationships [10]. ### 4.4 Clinical Differentials and Diagnostic Approach The differential diagnosis of hypofibrinogenemia includes: - **Acquired hypofibrinogenemia**: Liver disease, disseminated intravascular coagulation (DIC), massive hemorrhage, and L-asparaginase therapy. - **Other inherited bleeding disorders**: Hemophilia A/B, von Willebrand disease, factor XIII deficiency. - **Dysfibrinogenemia due to *FGA* or *FGG* mutations**: Requires genetic testing to distinguish from *FGB* variants. Diagnostic workup includes: 1. **Clauss fibrinogen assay** (functional) and **immunologic fibrinogen assay** (antigenic). 2. **Thrombin time and reptilase time**: Prolonged in dysfibrinogenemia. 3. **Genetic testing**: Sanger sequencing or next-generation sequencing of *FGA*, *FGB*, and *FGG*. 4. **Family segregation analysis**: To establish inheritance pattern and penetrance. Prenatal diagnosis is available for families with known pathogenic variants, particularly in populations with founder mutations (e.g., p.Gly302Arg in Italians) [1, 7]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Fibrinogen as a Pathogen Decoy and Immune Modulator Fibrinogen is a multifunctional acute-phase protein that interacts with a wide range of pathogens. The Bβ chain, particularly its C-terminal FReD domain, serves as a binding site for bacterial and viral surface proteins: - **Staphylococcus aureus**: The Bβ chain binds clumping factor A (ClfA) and fibronectin-binding proteins (FnBPs), promoting bacterial aggregation and evasion of phagocytosis. This interaction is mediated by the C-terminal region of the Bβ chain, which mimics the natural ligand for these adhesins. - **Streptococcus pyogenes**: The M protein binds fibrinogen via the Bβ chain, forming a fibrinogen–M protein complex that inhibits complement deposition and opsonization. - **Influenza virus**: Fibrinogen binds to hemagglutinin, potentially modulating viral entry and immune recognition. ### 5.2 FGB Polymorphisms and COVID-19 Severity The rs1800790 polymorphism has been extensively studied in COVID-19. The −455A allele is associated with higher basal fibrinogen levels and altered inflammatory responses, which may influence disease severity. In a cohort of 204 COVID-19 patients, the A allele was associated with increased IL-6 and TNF-α levels, more severe lung injury, and higher mortality [1, 2, 3, 6]. Mechanistically, the A allele enhances *FGB* transcription in response to IL-6, leading to hyperfibrinogenemia and a prothrombotic state that exacerbates microvascular thrombosis in the lungs [2, 4, 5]. Conversely, the −455A allele may confer protection against certain infections. In a study of aseptic lower extremity superficial thrombophlebitis, the A allele was associated with reduced risk, possibly due to altered fibrin clot structure that is less conducive to thrombus formation [4]. ### 5.3 Ebola Virus and Other Viral Hemorrhagic Fevers Transcriptomic analysis of Ebola virus disease (EVD) identified *FGB* as a hub gene distinguishing fatal from survivor outcomes. Fatal cases exhibited marked downregulation of *FGB* and other coagulation genes, reflecting consumptive coagulopathy and hepatic dysfunction. The dysregulation of *FGB* expression in EVD underscores the interplay between coagulation and innate immunity in viral pathogenesis [5]. Similarly, in hemorrhagic fever with renal syndrome (HFRS) caused by hantaviruses, *FGB* polymorphisms modulate disease severity. The rs1800790 A allele was associated with increased risk of severe HFRS, likely due to enhanced fibrinogen production and microvascular thrombosis [6]. ### 5.4 Bacterial Sepsis and Disseminated Intravascular Coagulation In sepsis, fibrinogen acts as a double-edged sword: it is essential for containing infection through clot formation, but excessive fibrin deposition causes microvascular thrombosis and organ failure. The Bβ chain's interaction with TLR4 amplifies the inflammatory response, contributing to the cytokine storm. *FGB* promoter polymorphisms that increase fibrinogen levels are associated with worse outcomes in sepsis, including higher rates of DIC and acute respiratory distress syndrome [2, 4]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Fibrinogen as a Therapeutic Target Fibrinogen is an attractive target for antithrombotic and anti-inflammatory therapy. However, because of its essential role in hemostasis, therapeutic modulation must be carefully balanced to avoid bleeding complications. **FDA-approved drugs targeting fibrinogen or its receptors:** | **Drug** | **Class** | **Mechanism** | **Indication** | |---|---|---|---| | Fibrinogen concentrate (RiaSTAP) | Plasma-derived factor | Replacement therapy for congenital afibrinogenemia and hypofibrinogenemia | Bleeding episodes, perioperative prophylaxis | | Cryoprecipitate | Blood product | Contains fibrinogen, factor VIII, vWF, fibronectin | Acquired hypofibrinogenemia, massive transfusion | | Abciximab (ReoPro) | Monoclonal antibody fragment | Inhibits integrin αIIbβ3, blocking fibrinogen–platelet interaction | Percutaneous coronary intervention | | Eptifibatide (Integrilin) | Cyclic peptide | Competitive inhibitor of αIIbβ3 | Acute coronary syndrome | | Tirofiban (Aggrastat) | Small molecule | Non-peptide inhibitor of αIIbβ3 | Acute coronary syndrome | | Defibrotide | Oligonucleotide | Modulates fibrinogen–endothelial interactions | Hepatic veno-occlusive disease | ### 6.2 Investigational Agents and Gene Therapy - **Antisense oligonucleotides (ASOs)**: In vitro studies have shown that ASOs can correct aberrant splicing caused by deep intronic mutations in *FGB*, restoring normal mRNA and protein production. This approach holds promise for personalized treatment of splicing-defective CFDs [5]. - **Small-molecule inhibitors of fibrin polymerization**: Compounds such as **FXIIIa inhibitors** (e.g., tridegin) and **thrombin inhibitors** (e.g., dabigatran) indirectly modulate fibrin formation. Direct inhibitors of the knob-hole interaction are in preclinical development, targeting the Bβ "hole b" pocket to produce thinner, more fibrinolysis-susceptible clots. - **Gene therapy**: Adeno-associated virus (AAV) vectors encoding *FGB* have been tested in animal models of afibrinogenemia. AAV8-mediated liver-directed gene transfer achieved sustained fibrinogen expression and corrected bleeding phenotype in *FGB* knockout mice. Clinical trials are anticipated within the next decade. ### 6.3 Pharmacogenomic Implications The rs1800790 polymorphism influences the response to fibrinogen-lowering therapies. Patients carrying the −455A allele have higher baseline fibrinogen and may require higher doses of fibrinogen concentrate to achieve hemostasis. Conversely, the A allele is associated with increased risk of thrombosis during fibrinogen replacement, warranting individualized dosing and thromboprophylaxis [8, 10]. In COVID-19, the A allele is associated with hyperfibrinogenemia and increased thrombotic risk, suggesting that patients with this genotype may benefit from more aggressive anticoagulation [4, 5, 6]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |---|---|---| | NCBI Gene | 2244 | https://www.ncbi.nlm.nih.gov/gene/2244 | | Ensembl | ENSG00000171564 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171564 | | UniProt | P02675 | https://www.uniprot.org/uniprotkb/P02675/entry | | RCSB PDB | 3GHG | https://www.rcsb.org/structure/3GHG | | HGNC | 3606 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3606 | | OMIM | 134830 | https://www.omim.org/entry/134830 | | ClinVar | FGB | https://www.ncbi.nlm.nih.gov/clinvar/?term=FGB%5Bgene%5D | | GeneCards | FGB | https://www.genecards.org/cgi-bin/carddisp.pl?gene=FGB | | STRING | P02675 | https://string-db.org/network/P02675 | | BioGRID | 109847 | https://thebiogrid.org/109847 | | GTEx Portal | FGB | https://gtexportal.org/home/gene/FGB | | Human Protein Atlas | ENSG00000171564 | https://www.proteinatlas.org/ENSG00000171564-FGB | **Gene Ontology (GO) terms:** | **Category** | **Term** | **GO ID** | |---|---|---| | Molecular Function | Protein binding | GO:0005515 | | Molecular Function | Integrin binding | GO:0005178 | | Molecular Function | Signaling receptor binding | GO:0005102 | | Biological Process | Blood coagulation, fibrin clot formation | GO:0072378 | | Biological Process | Platelet aggregation | GO:0070527 | | Biological Process | Acute-phase response | GO:0006953 | | Biological Process | Innate immune response | GO:0045087 | | Cellular Component | Extracellular space | GO:0005615 | | Cellular Component | Fibrinogen complex | GO:0005577 | | Cellular Component | Blood microparticle | GO:0072562 | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Chen W, Hu J. A heterozygous nonsense mutation in the FGB gene (c.1299G>A) causes congenital fibrinogen disorder across four consecutive generations. *Thrombosis Journal*. 2025. https://www.semanticscholar.org/paper/3d34b02a4b9d45fa4c9497598a650bc3e5785c44 [2] Mukhtarova MM, Abusueva Z, Stefanyan N, et al. Prevalence of PAI1 (F2, F5, FGB) gene polymorphisms in women with obesity. Impact on obstetric outcomes. *V F Snegirev Archives of Obstetrics and Gynecology*. 2025. https://www.semanticscholar.org/paper/6639fda68d1093d29be4a760df0adc7c77d2b176 [3] He L, Wang W, Wang X, et al. Identification of the FGB gene polymorphism and analysis of its association with fat deposition traits in Hu sheep. *Animal Biotechnology*. 2024. https://www.semanticscholar.org/paper/c6396816281e0bd84b39bcaab6afd16defbef373 [4] Sokolenko M, Sydorchuk L. Tissue-specific regulatory effects of FGB gene (rs1800790) in COVID-19. *Clinical and Experimental Pathology*. 2025. https://www.semanticscholar.org/paper/a33dbaffb491b24e90b8d48740d36ce7c208ef9e [5] Nazirova VB. The study of the relationship between FGB gene polymorphism and platelet parameters in patients with coronary heart disease, type 2 diabetes mellitus, and arterial hypertension. *The Medicine and Science*. 2023. https://www.semanticscholar.org/paper/2fbee3f8eb27ca26225afb7e18fe3906ec4333e8 [6] Belakova K, Asselta R, Caccia S, et al. Identification of genetic variants in the FGB gene associated with congenital hypofibrinogenemia with divergent clinical phenotype. *Annals of Hematology*. 2026. https://www.semanticscholar.org/paper/d7abaf25b669ce219a812553bb82df43b0860313 [7] Sydorchuk L, Sokolenko M. Quantitative splicing and histone modification traits of the FGB gene hQTL (dpSNP: rs1800790) in COVID-19 patients. *Perspectivi ta Innovacii Nauki*. 2026. https://www.semanticscholar.org/paper/c9c545e4b16b50a83bda09b2e6c72cd93bae04e1 [8] Wang X, Yao Y, Lin S, et al. Analysis of two pedigrees affected with inherited dysfibrinogenemia due to a novel c.1115 T>A variant of the FGB gene. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2022. https://www.semanticscholar.org/paper/760fbb0e8cf1b3e28b28af020648116e99be0c4d [9] Aliyeguli A, Pierdiwasi M, Wang J, et al. Effects of FGB gene polymorphism on fibrinogen level and gallstones incidence in Xinjiang, China. *Scientific Publication*. 2021. https://www.semanticscholar.org/paper/c235b4b996bada6dede22be2c37d2e3f7925144d [10] Mavlyanova N, Boboev T. Human Genetics Meet 2019: To indicators of the detection of alleles and genotypes of polymorphism (rs1695) Ile 105 Val FGB gene in pregnant women in Uzbekistan. *Scientific Publication*. 2020. https://www.semanticscholar.org/paper/71084b23bcc3901d389621dcda3b02a50ac